Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada in a report released on Wednesday, November 8th, StockTargetPrices.com reports. They presently have a C$23.00 price target on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 9.32% from the company’s current price.
Separately, TD Securities upped their price target on Valeant Pharmaceuticals International to C$26.00 and gave the stock a “hold” rating in a research report on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of C$22.50.
Shares of Valeant Pharmaceuticals International (VRX) traded down C$0.03 during mid-day trading on Wednesday, hitting C$21.04. The stock had a trading volume of 1,094,602 shares, compared to its average volume of 1,431,692. Valeant Pharmaceuticals International has a 1-year low of C$11.20 and a 1-year high of C$23.75.
COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals International, Inc. (TSE:VRX) Earns Sector Perform Rating from Royal Bank Of Canada” was reported by BBNS and is the sole property of of BBNS. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://baseballnewssource.com/markets/valeant-pharmaceuticals-intl-inc-vrx-rating-reiterated-by-royal-bank-of-canada/1766098.html.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with our FREE daily email newsletter.